Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 615

1.

FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study.

Iwamoto S, Takahashi T, Tamagawa H, Nakamura M, Munemoto Y, Kato T, Hata T, Denda T, Morita Y, Inukai M, Kunieda K, Nagata N, Kurachi K, Ina K, Ooshiro M, Shimoyama T, Baba H, Oba K, Sakamoto J, Mishima H.

Ann Oncol. 2015 Apr 23. pii: mdv197. [Epub ahead of print]

PMID:
25908603
2.

The efficacy of adjuvant immunochemotherapy with OK-432 after curative resection of gastric cancer: an individual patient data meta-analysis of randomized controlled trials.

Oba MS, Teramukai S, Ohashi Y, Ogawa K, Maehara Y, Sakamoto J.

Gastric Cancer. 2015 Mar 25. [Epub ahead of print]

PMID:
25804300
3.

Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial.

Nishikawa K, Fujitani K, Inagaki H, Akamaru Y, Tokunaga S, Takagi M, Tamura S, Sugimoto N, Shigematsu T, Yoshikawa T, Ishiguro T, Nakamura M, Morita S, Miyashita Y, Tsuburaya A, Sakamoto J, Tsujinaka T.

Eur J Cancer. 2015 May;51(7):808-16. doi: 10.1016/j.ejca.2015.02.009. Epub 2015 Mar 18.

4.

Impact of airflow limitation on carotid atherosclerosis in coronary artery disease patients.

Hamrah MS, Suzuki S, Ishii H, Shibata Y, Tatami Y, Osugi N, Ota T, Kawamura Y, Tanaka A, Aso H, Takeshita K, Sakamoto J, Hasegawa Y, Murohara T.

Respiration. 2015;89(4):322-8. doi: 10.1159/000375313. Epub 2015 Mar 17.

5.

Differentiating benign and malignant salivary gland tumours: diagnostic criteria and the accuracy of dynamic contrast-enhanced MRI with high temporal resolution.

Lam PD, Kuribayashi A, Imaizumi A, Sakamoto J, Sumi Y, Yoshino N, Kurabayashi T.

Br J Radiol. 2015 May;88(1049):20140685. doi: 10.1259/bjr.20140685. Epub 2015 Mar 20.

PMID:
25791568
6.

Impact of the cardiac arrest mode on cardiac death donor lungs.

Yamada T, Chen F, Sakamoto J, Nakajima D, Ohsumi A, Bando T, Date H.

J Surg Res. 2015 May 15;195(2):596-603. doi: 10.1016/j.jss.2015.02.029. Epub 2015 Feb 19.

PMID:
25777821
7.

Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response.

Hashimoto N, Tsuboi A, Kagawa N, Chiba Y, Izumoto S, Kinoshita M, Kijima N, Oka Y, Morimoto S, Nakajima H, Morita S, Sakamoto J, Nishida S, Hosen N, Oji Y, Arita N, Yoshimine T, Sugiyama H.

Cancer Immunol Immunother. 2015 Mar 14. [Epub ahead of print]

PMID:
25772149
8.

[A case of small intestinal lymphoma with ileus requiring surgery during chemotherapy].

Wakiya T, Shibata S, Sutou T, Narita J, Iino C, Sakamoto J, Yamanaka Y.

Gan To Kagaku Ryoho. 2014 Nov;41(12):2453-5. Japanese.

PMID:
25731555
9.

Brain derived neurotrophic factor release from layer-by-layer coated agarose nerve guidance scaffolds.

Lynam DA, Shahriari D, Wolf KJ, Angart PA, Koffler J, Tuszynski MH, Chan C, Walton P, Sakamoto J.

Acta Biomater. 2015 May;18:128-31. doi: 10.1016/j.actbio.2015.02.014. Epub 2015 Feb 21.

PMID:
25712385
10.

A prospective analysis of clinical efficacy and safety in chronic myeloid leukemia-chronic phase patients with imatinib resistance or intolerance as evaluated using European LeukemiaNet 2013 criteria.

Murai K, Akagi T, Shimosegawa K, Sugawara T, Ishizawa K, Ito S, Murai K, Motegi M, Yokoyama H, Noji H, Tajima K, Kimura J, Chou T, Ogawa K, Harigae H, Kubo K, Oba K, Sakamoto J, Ishida Y.

Eur J Haematol. 2015 Feb 19. doi: 10.1111/ejh.12536. [Epub ahead of print]

PMID:
25703064
11.

Multipotent adult progenitor cells decrease cold ischemic injury in ex vivo perfused human lungs: an initial pilot and feasibility study.

La Francesca S, Ting AE, Sakamoto J, Rhudy J, Bonenfant NR, Borg ZD, Cruz FF, Goodwin M, Lehman NA, Taggart JM, Deans R, Weiss DJ.

Transplant Res. 2014 Nov 1;3(1):19. doi: 10.1186/2047-1440-3-19. eCollection 2014.

12.

Effects of Vibration Therapy on Immobilization-Induced Hypersensitivity in Rats.

Hamaue Y, Nakano J, Sekino Y, Chuganji S, Sakamoto J, Yoshimura T, Okita M, Origuchi T.

Phys Ther. 2015 Feb 5. [Epub ahead of print]

PMID:
25655883
13.

Upregulation of IL-1β/TGF-β1 and hypoxia relate to molecular mechanisms underlying immobilization-induced muscle contracture.

Honda Y, Sakamoto J, Nakano J, Kataoka H, Sasabe R, Goto K, Tanaka M, Origuchi T, Yoshimura T, Okita M.

Muscle Nerve. 2014 Dec 30. doi: 10.1002/mus.24558. [Epub ahead of print]

PMID:
25641164
14.

Phase II study on hepatic arterial infusion chemotherapy using percutaneous catheter placement techniques for liver metastases from colorectal cancer (JFMC28 study).

Arai Y, Aoyama T, Inaba Y, Okabe H, Ihaya T, Kichikawa K, Ohashi Y, Sakamoto J, Oba K, Saji S.

Asia Pac J Clin Oncol. 2015 Mar;11(1):41-8. doi: 10.1111/ajco.12324. Epub 2015 Jan 12.

PMID:
25628061
15.

Geometrical parameter analysis of a high-sensitivity fiber optic angular displacement sensor.

Sakamoto JM, Pacheco GM, Kitano C, Tittmann BR.

Appl Opt. 2014 Dec 20;53(36):8436-43. doi: 10.1364/AO.53.008436.

PMID:
25608191
16.

Prevalence of esophageal cancer in the Northern part of Afghanistan.

Hamrah MS, Hamrah MH, Rabi M, Wu HX, Hao CN, Harun-Or-Rashid M, Sakamoto J, Ishii H.

Asian Pac J Cancer Prev. 2014;15(24):10981-4.

17.

[A case of recurrent gastric cancer successfully treated with S-1 oral administration].

Maeda H, Okamoto K, Sakamoto J, Usui T, Kawamura A, Tamura S, Takeshita A, Kobayashi M.

Gan To Kagaku Ryoho. 2015 Jan;42(1):89-92. Japanese.

PMID:
25596686
18.

Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group.

Iriyama N, Fujisawa S, Yoshida C, Wakita H, Chiba S, Okamoto S, Kawakami K, Takezako N, Kumagai T, Inokuchi K, Ohyashiki K, Taguchi J, Yano S, Igarashi T, Kouzai Y, Morita S, Sakamoto J, Sakamaki H.

Am J Hematol. 2015 Apr;90(4):282-7. doi: 10.1002/ajh.23923. Epub 2015 Mar 2.

PMID:
25530131
19.

Efficacy of molecular response at 1 or 3 months after the initiation of dasatinib treatment can predict an improved response to dasatinib in imatinib-resistant or imatinib-intolerant Japanese patients with chronic myelogenous leukemia during the chronic phase.

Inokuchi K, Kumagai T, Matsuki E, Ohashi K, Shinagawa A, Hatta Y, Takeuchi J, Yoshida C, Wakita H, Kozai Y, Shirasugi Y, Fujisawa S, Iwase O, Yano S, Okamoto S, Oba K, Sakamoto J, Sakamaki H.

J Clin Exp Hematop. 2014;54(3):197-204.

20.

Evaluation of knowledge, practices, and possible barriers among healthcare providers regarding medical waste management in Dhaka, Bangladesh.

Sarker MA, Harun-Or-Rashid M, Hirosawa T, Abdul Hai MS, Siddique MR, Sakamoto J, Hamajima N.

Med Sci Monit. 2014 Dec 9;20:2590-7. doi: 10.12659/MSM.890904.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk